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ABSTRACT

TOTAL SYNTHESIS OF CLAVATADINE A ANALOGS TO PRODUCE A VIABLE
REVERSIBLE INHIBITOR FOR FACTOR XIA
by
Christopher Eric Malmberg
June 2015
Cardiovascular disease has quickly become a major health concern in the United
States, with numerous citizens dying from cardiovascular disease each year. Older
medications, while effective against cardiovascular disease, are problematic to prescribe.
A recently isolated natural product, clavatadine A, selectively inhibits human blood
coagulation factor XIa. As a result, the synthesis and biological testing of clavatadine A
and synthetic clavatadine A analogues that selectively inhibit factor XIa would represent
a new direction in cardiovascular disease research. A potent and selective factor XIa
inhibitor has the potential to be a safer replacement for current anticoagulants, such as
Warfarin, Pradaxa®, Eliquis®, and Xarelto®. The first total synthesis of clavatadine A was
recently completed. Clavatadine A binds irreversibly to the active site of factor XIa;
therefore, a primary goal of this research is to design an analogue of clavatadine A that is
a selective, reversible factor XIa inhibitor. The general approach developed for the
synthesis of guanidine containing natural products was used to attempt to prepare several
synthetic analogues of clavatadine A. First, the original four analogues of clavatadine A
iii

that included a urea, reverse carbamate and two amide analogues were attempted in hopes
to synthesize an analogue that was less likely to form a covalent bond with Ser-195 in the
active site of factor XIa. Phase two analogues were also attempted when the orginal four
analogues did not work out as planned. Phase two included attempting to make a five
carbon clavatadine A.
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CHAPTER 1:
INTRODUCTION
1.1: Cardiovascular Disease
Cardiovascular disease has quickly become the leading cause of death for humans
in the developed world, causing 23% of all deaths in the United States in 2011.1
Cardiovascular disease is a broad term that encompasses many conditions that involve the
heart, arteries, capillaries and veins. The most notorious manifestations of cardiovascular
disease include ischemic stroke, myocardial infarction, pulmonary embolism (blood flow
is obstructed within the lung), peripheral artery disease, and deep vein thrombosis.2
These cardiovascular conditions can be caused when the body loses control of
hemostasis, which is the process of controlling how blood coagulates and how
coagulation is regulated.3 Unregulated coagulation can result in either the inhibition of
clotting (leading to hemophilia), or hyperactivity of coagulation (leading to thrombosis).
Thrombosis is a leading cause of cardiovascular disease manifestations, and is the main
target in preventing cardiovascular diseases.4 When there is a hyperactivity of
coagulation, a thrombus (blood clot) is usually made, which can become lodged in a
blood vessel and obstruct blood flow. Some examples of a thrombus traveling and getting
lodged in a blood vessel are ischemic strokes and myocardial infarction, which is when a
thrombus is lodged in a blood vessel in the brain or heart, respectively. These conditions
can also occur from sitting too long while traveling, having an inactive lifestyle, or just
not being able to move extremities (paraplegia), and will most likely cause peripheral
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artery disease (the obstruction of large arteries in limbs) and deep vein thrombosis (the
obstruction of veins in limbs).4
For hemostasis to function properly
it relies heavily on the blood coagulation
pathway, which is made up of two pathways
that involve serine proteases and proteinprotein interactions to form fibrin, and
ultimately form a thrombus to stop
hemorrhaging (Figure 1-1).5,6 The first
pathway is the tissue-factor pathway
(extrinsic), which is activated when factor
Figure 1-1: Coagulation cascade

VII is exposed to the extravascular
membrane protein, tissue factor (TF), at an injury site, and forms a complex that activates
factor VIIa (FVIIa).2,6 Factor VIIa-TF complex then activates factor X to Xa that then
forms a complex with factor Va to cleave prothrombin into thrombin.6,7 Thrombin then
activates more platelets and causes fibrin to form in order to stop hemorrhaging.5 The
contact-activation pathway (intrinsic) functions in the same way as the tissue factor
pathway, except that it is activated by factor XII coming in contact with a negatively
charged surface and forming factor XIIa. Factor XIIa then goes on to activate factor XI to
XIa, which then activates factor IX to IXa. Once factor IXa is activated the two pathways
begin to merge because IXa activates factor X to Xa, which leads to the formation of
fibrin as in the tissue factor pathway.6,7 Fibrin is a protein that works with platelets in the
2

blood to form a hemostatic plug or clot. For clotting to occur properly all of the serine
protease enzymes must function properly. If one serine protease does not function
properly, then the whole pathway will not create fibrins, and clotting will not occur. If
this situation is left untreated, coagulation disorders like hemophilia (excessive bleeding)
or thrombosis (excessive clotting) can occur, with the latter being the main cause of
cardiovascular conditions.
1.2: Past and Present Treatments
Cardiovascular disease can be managed with medication, but the commonly
prescribed medications can cause more harm than good if not monitored carefully. The
most commonly prescribed medications used to treat thrombosis-related conditions over
the last sixty years are warfarin and heparin.8 Although warfarin and heparin are effective
at blood thinning, the dose given to a patient must be carefully monitored because an
overdose can easily result in excessive bleeding and other complications arising from
interactions with other pharmaceutical drugs or food.8 Warfarin and heparin are not ideal
cardiovascular disease medications because they are non-specific inhibitors and can
interact with similar or even unrelated proteins and cause unwanted side effects. To
eliminate the complications of the unwanted side effects, scientists and pharmaceutical
companies have directed drug discovery efforts towards specific coagulation factors.
New anticoagulation drugs have become available that specifically target
coagulation pathway proteins, and seem to avoid some of the complications that plagued
warfarin and heparin. Two of the new drugs on the market in 2012 and 2013 are
rivaroxaban (Xarelto®, manufactured by Bayer) and apixiban (Eliquis®, manufactured by
3

Bristol-Myers Squibb), which target and inhibit coagulation factor (FXa).4 Another drug
approved by the FDA for treatment of strokes was dabigatran etexilate (Pradaxa®,
manufactured by Boehringer-Ingelheim), which targets and inhibits thrombin (FIIa).9 All
of these anticoagulation drugs show an improvement over warfarin and heparin in terms
of their therapeutic index (toxicity dose divided by effective dose) and they may prove to
be safer for patients.
However, these new medications still have some of the same drawbacks as
warfarin and heparin, which when taken by a patient can cause substantial bleeding risk if
trauma occurs.9,10 Even with an improved therapeutic index, doctors must monitor doses
closely and administer antidotes to the anticoagulant medications if severe bleeding
occurs.11 These new medications are more precise than old medications because they are
targeting specific coagulation factors with fewer side effects. Unfortunately, these new
medications are targeting coagulation factors that are essential to form clots. Therefore,
once one of these coagulation factors has been inhibited, the coagulation pathway may
cease to function, thus disrupting hemostasis and preventing clots from forming. These
medications, while not perfect, do have ideal anticoagulant characteristics like
reversibility and specificity, and show progress towards a treatment for thrombosis.12
One way to treat thrombosis without the risk for excessive bleeding is to target a
coagulation factor that is part of the amplification phase of a clot, and not the
construction phase. Factor XIa is an interesting target because its structural features
distinguish it from vitamin K-dependent proteases. Because it is being made up of four
apple domains, it resembles α-kallikrein more than other blood coagulation proteases.13
4

Studies have suggested that inhibiting factor XIa (FXIa) could treat thrombosis while
leaving the coagulation pathway intact and allowing clotting to occur.2,3,9,12 While other
drugs have targeted different proteins in the coagulation pathway, factor XIa is a more
suitable target because it has the potential to be inhibited without the disadvantage of
disrupting the coagulation pathway.10 This is possible because factor XIa is part of the
amplification phase of the intrinsic pathway, so once the pathway has been activated,
factor XIa helps to increase the clot size. Developing a molecule that can inhibit factor
XIa into a drug, and thus slowing down the rate at which clots grow is promising because
studies on patients with factor XIa deficiency (hemophilia C) have shown that there
might not be a high bleeding risk unless major trauma is involved.3 Therefore, a
medication that is a specific inhibitor of factor XIa may also reduce complications and
have a higher therapeutic ratio than any previous thrombosis medication.
Recently, factor XIa has become a prime target to treat cardiovascular disease,
with numerous new molecules being discovered and tested in the last few years. Most of
these newly discovered molecules or analogues target the allosteric site of factor XIa in
order to have a greater specificity to factor XIa over structurally-related serine proteases.
This occurs by a molecule targeting a site on factor XIa that is not its active site, once the
molecule binds to factor XIa it negatively inhibits the factor by altering the active site and
not allowing it to bind to factor IX. One of those molecules is a derivative of
tetrahydroquinoline a very potent inhibitor with a Ki value of 0.20 nM .14 Unfortunately,
this derivative is also potent kallikrein inhibitors, which can cause cardiovascular
problems involving blood pressure and other problems related to kallikrein functions.14,15
5

Another newly discovered molecule is hydroxyquinolin-2(1H)‑one, which has a Ki value
of 0.04 nM for factor XIa.16 Hydroxyquinolin-2(1H)‑one, however, suffers from the same
drawbacks as the tetrahydroquinoline derivative, in that it is also a potent inhibitor of
kallikrein.16 This complication could arise from the fact that factor XIa and α-kallikrein
are trypsin-like enzymes and come from the same chymotrypsin family of serine
proteases.17 This complication can also affect active site binders if the designed molecule
is not selective enough.17
1.3: Clavatadine A and Analogues
A molecule that has shown the ability to inhibit factor XIa specifically is the
recently isolated natural product clavatadine A.18 With an IC50 of 1.3 μM for factor XIa,
clavatadine A offers promise as an anticoagulant medication.18 The Chamberland
research group at Central Washington University was able to successfully synthesize
clavatadine A for the first time in a laboratory using a streamlined approach (Figure 12)19. This approach broke clavatadine A down into two manageable molecules; a
dibromophenol (2) and a protected guanidine side chain (1)19. These pieces were then

Figure 1-2: Clavatadine A synthesis

joined together by reacting an isocyanate with a dibromophenol to form the carbamate
functional group that links the two pieces together to create a precursor of clavatadine
6

(3)19.Unfortunately, clavatadine A has one imperfection that keeps it from being an ideal
anticoagulant, it is an irreversible binder to factor XIa.18 Clavatadine A is an irreversible
inhibitor because when it enters the active site of factor XIa it binds with strong non-

Figure 1-3: Clavatadine A bound to factor XIa

covalent interactions. Once securely in the active site (Figure 1-3) , a nucleophilic alcohol
of serine 195 from factor XIa attacks the carbamate of clavatadine A and forms an
irreversible covalent bond.18 This bond formation expels the aromatic portion and leaves
the linear portion adhered to the active site. Bound to clavatadine A, factor XIa is
rendered useless, which forces the body to destroy and remake the factor before it can be
used to amplify clots. It is the goal of the
Chamberland research group to extend the
success of synthesizing clavatadine A by
developing four first generation analogues of
clavatadine A for a new medicinal chemistry
program. These analogues are designed to be
reversible inhibitors of factor XIa by having a
less-labile group that interacts with serine 195
Figure 1-4: Original four analogues

but prevents cleaving of the molecule (Figure

1-4). This hypothesis will be tested by replacing the carbamate of clavatadine A with
7

less-labile functional groups like an amide (7, 8), urea (6), or reverse carbamate (5).
These new functional groups if successful will cause serine 195 to form a strong
electrostatic interaction with the electrophilic carbonyl carbon of the functional groups,
but should prevent cleavage of the molecule.
Since these analogues are so similar to clavatadine A, routes that are similar to the
synthetic route to make clavatadine A will be used to produce the analogues, but with
slight modifications for the new molecules. As in the clavatadine A synthesis, each
analogue will be broken into two pieces, a dibromolactone portion and a protected
guanidine side chain. Three of the analogues will start with the nitration of 2coumaranone, which will then go through a nitro reduction to produce an aniline that will
then be brominated to produce the needed dibromoaniline. The linear guanidine side
chain will be produced in the identical manner for the urea, and for one of the amide
analogues. The reverse carbamate linear guanidine chain will start by protecting a 2methyl-2-thiopseudourea sulfate, and then reacting it with the necessary side chain.
While planning for these first four analogues many other analogues that could be easily
obtained by using the same subunits as the original four along with subunits form
clavatadine A. These other analogues include clavatadine A and the orginal analogues,
but with a five-carbon chains instead of a four-carbon chains, also replacing the
carbamate or urea with a thiocarbamate or thiourea functional group. Adding an extra
carbon could move the carbamate far enough away from serine 195 that it cannot
covalently bond, while the sulfur atom is less electronegative and may make the carbonyl
carbon less of a target for attack from the nucleophilic oxygen of serine 195. Once
8

enough of each of these analogues is made they will then be tested using in vitro enzyme
assays to determine their affinity for factor XIa and other enzymes, and to see if they are
reversible and strong inhibitors.
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Chapter 2:
Synthesizing the Subunits
2.1: Designing the analogues
The original compounds that were chosen for synthesis were a urea, reverse
carbamate, and amide analogues of clavatadine A. These four analogues were chosen in
an attempt to make the carbamate functional group in clavatadine A less labile, making it
less prone to attack from the hydroxyl group of serine 195 in factor XIa. While working
towards the original analogues, several more easily obtainable analogues were planned
using the same or similar subunits that would create the first four analogues, or by
modifying the carbamate by replacing the carbonyl oxygen with a less electronegative
atom.
To make all of these analogues, the same convergent scheme that included an
early guanidinylation method that created clavatadine A was used.19 This involved
breaking the molecule down into two subunits, a lactone subunit and a linear, guanidine
containing subunit. These two subunits would later be joined together using an isocyanate
to form a carbamate. Each analogue like clavatadine A was broken down into its lactone
and linear, guanidine containing subunits by breaking the carbonyl containing functional
group in the middle of the molecules. This left many new subunits that needed to be
synthesized, along with subunits that could be reused from the clavatadine A synthesis.
These subunits may later be joined together using an isocyanate or chloroformate
functional group.
11

2.2: Creating the Lactones
Retrosynthetic analysis showed that the target analogues could be synthesized by
using only two different lactone subunits. The first lactone subunit that was synthesized
was 4,6-dibromohomogentisic acid lactone, which is the same lactone subunit that was
used to create clavatadine A.19 This first lactone subunit was synthesized by first taking
2,5-(dimethoxyphenyl)acetic acid (9) and treating it with HBr to give homogentisic acid
lactone (Figure 2-1).19
MeO

OH
O
OMe

HBr (aq)

HO
O

96%

O
10

9
Figure 2-1: Synthesis of homogentisic acid lactone

With o-hydroxyphenylacetic acid in its lactone form the highly reactive and polar
molecule can undergo further reactions and purification without fear of unwanted side
reactions taking place. The crude product of this reaction was then purified using
decolorizing carbon and recrystallization, to obtain a low yield of product. It was then
found that these steps could be eliminated to give a pure product with a yield of 96% to
97%, when a 1H NMR spectrum was taken of the crude product before recrystallization
in an attempt to discover why the reaction produced a low yield. The homogentisic acid
lactone (10) was then brominated using Br2 and NaOAc in acetic acid, to obtain 4,6dibromohomogentisic acid lactone (2) at a yield of 68%.19 Both bromines add ortho to

12

the hydroxy group because it is an ortho, para director (figure 2-2). The first bromine
adds to C-6 of the ring because that site is less sterically hindred.

Figure 2-2: Synthesis of dibrominated homogentisic acid lactone

To synthesize the next lactone subunit a different method had to be employed
because the hydroxy group needed to be replaced with an amino group. Retrosynthetic
analysis showed that to synthesize the dibrominated aniline that was needed for
analogues 5-7, it was more cost effective and efficient to start with 2-coumaranone (11).
2-Coumaranone (11) was subjected to a simple nitration reaction by dissolving it in acetic

O
O

H2SO4, HNO3 O2N
Acetic Acid
70%

11

O
O
12

Figure 2-3: Synthesis of nitro coumaranone

acid and adding it to a solution of HNO3 and H2SO4 (Figure 2-3).20 This reaction
provided a yield of 50% or less at first, until the reaction was split up into multiple flasks
and allowed to stir for a longer amount of time, which provided a yield of 70%. This nitro
coumaranone (12) was subjected to a reduction reaction using hydrogen gas and a
palladium on carbon catalyst to reduce the nitro group to an amino group (Figure 2-4).
This reaction was successful while working with small quantities, providing a yield of
99%. When tried on a large scale however, over 400 mg, the reaction would take longer

13

and could lead to dimerization of the newly formed amino coumaranone (13) with

Figure 2-4: Forming amino coumaranone

another amino coumaraone (13) or nitro coumaraone (12). This occurs because esters or
lactones are extremely susceptible to attacks from amines, when in contact with one
anonther these molecules can go through an aminoylsis reaction. The amino
coumaranone (13) was then brominated by dissolving it in ethyl acetate and adding Br2
(Figure 2-5).
Br

H2N
O
O
13

Br2

H2N
o

EtOAc, -78 C
40%

O
Br

O
14

Figure 2-5: Forming the dibrominated amino coumaranone

This reaction provided a yield of 40% dibrominated amino coumaranone (14), with the
monobrominated amino coumaranone as the major product. With the two lactones
successfully synthesized it was time to synthesize the many linear, guanidine containing
subunits.
2.3: Linear guanidine containing subunits
Retrosynthetic analysis showed that four different linear, guanidine containing
subunits needed to be synthesized to complete all the desired analogues. One of the four
linear chains included the same linear subunit that was used to make clavatadine A.
Another contained a linear chain with one extra CH2 resulting in a five carbon chain
instead of a four carbon chain. First all the linear, guanidine containing subunits were
14

synthesized by starting with an N,Nʹ-di-Boc guanidine (16). To synthesize N,Nʹ-di-Boc
guanidine (16) a solution of guanidine hydrochloride (15) dissolved in 1,4 dioxane was
treated with di-tert-butyl dicarbonate and sodium hydroxide, providing a yield of 56%
(figure 2-6).21

Figure 2-6: Forming N,Nʹ-di-Boc guanidine (16)

The N,Nʹ-di-Boc guanidine (16) was then dissolved in dichloromethane, and treated with
triflic anhydride under anhydrous and high dilution conditions to produce N,N-di-Boc-
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Figure 2-7: Synthesis of Goodman’s reagent

Nʹ-triflylguanidine (17), or better known as a Goodman’s reagent at a 46% yield (Figure
2-7).21 N,N-di-Boc-Nʹ-triflylguanidine (17) was then reacted with 1,4-butanediamine (18)
by using a modified version of the procedure that Botta et al. and Munoz et al.
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Figure 2-8: Synthesis of the four carbon linear chain

developed.22,23 This lead to the first linear, guanidine containing subunit (19) that was
needed for the analogues (Figure 2-8).22 To create the linear, guanidine containing

15

subunit that has a five carbon chain (21), the exact same method was employed, except
the Goodman’s reagent was reacted with 1,5-pentanediamine (20) (Figure 2-9).22

Figure 2-9: Synthesis of five carbon linear chain

The last two linear, guanidine containing subunits that needed to be synthesized
all had a terminal hydroxyl group on the end of the carbon chain instead of an amine. Due
to the potential of the same method not working, a new method to create the hydroxy
linear, guanidine containing subunits was employed. This new method started out with 2methyl-2-thiopseudourea (22) being treated with di-tert-butyl dicarbonate and sodium
bicarbonate to give 1,3-bis(tert-butoxycarbonyl)-2-methyl-2-thiopseudourea (23) with a
yield of 82% (Figure 2-10).24,25 This compound was then refluxed with either 4-amino-1-

Figure 2-10: Forming 1,3-Bis(tert-butoxycarbonyl)-2-methyl-2thiopseudourea

butanol or 5-amino-1-pentanol (24) to give the desired linear, guanidine containing
subunits (25) with a terminal hydroxy group (Figure 2-11).26 The reaction with 4-amino1-butanol was not attempted because of the cost and amount of 4-amino-1-butanol, which
was only going to be attempted if the synthesis of the reverse carbamate analogue with
the five carbon chain was successful. Later on in the synthesis of the clavatadine A
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analogues the method used to create linear, guanidine containing subunits with terminal

24
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Figure 2-11: Synthesis of five carbon hydroxyl linear chain

amines was tested using 5-amino-1-pentanol (24) to see if the reaction was capable of
creating all four analogues.22 The reaction was successful, so only the Goodman’s reagent
method was later employed.
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Chapter 3:
Attempting the Analogues
3.1: Urea Analogue
Once all the subunits were successfully synthesized it was time to start joining
them together to create analogue precursors. As in the synthesis of clavatadine A, the two
subunits were connected by converting the terminal amine of the linear, guanidine
containing subunit (19) into a highly reactive and electrophilic isocyanate (26) and then
reacting that with a dibrominated lactone (2) that acted as a nucleophile. The analogue
subunits would be connected following the same method, by either using an isocyanate of
chloroformate functional group.
Initially the first analogue that was attempted was the urea analogue (25) , and

Figure 3-1: Synthesis of the isocyanate (26)

this involved converting the amine on the linear guanidine containing chain (19) to an
isocyanate group using triphosgene (Figure 3-1).27 Once the isocyanate (26) was
confirmed an FTIR peak at 2265 cm-1, it was then dissolved in dichloromethane and a
catalytic amount of Hünig’s base added to it, before dibrominated amino coumaranone
(in DCM) was added dropwise (Figure 3-2).19,28,29 This solution was then allowed to stir
for thirty minutes. TLC did show new spots, so the crude product was tested using 1H
NMR spectroscopy for the appearance of two N-H peaks signaling that a urea functional
group was formed between the two subunits. The NMR analysis revealed no evidence of
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this occurring. The same reaction was repeated to see if any of the urea analogue could be
formed using this method, but still no evidence of the urea analogue forming. It was then
decided to attempt the same reaction, but with the isocyanate on the dibrominated amino
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Figure 3-2: Synthesis of the urea analogue scheme 1

coumaranone (28) instead of the linear chain to see if the urea analogue could be formed.
To do this, the dibrominated amino coumaranone (14) was dissolved in ethyl acetate,
treated with triphosgene, and allowed to reflux for five hours (Figure 3-3).30,31 Again,
FTIR confirmed an isocyanate peak, at 2274 cm-1. The isocyanate was then dissolved in
dichloromethane and a catalytic amount of base added to it before the linear chain (19)
Br
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Figure 3-3: Synthesis of amino coumaranone isocyanate (28)

was added dropwise (Figure 3-5).28,29 This new method also showed no evidence of the
urea analogue being formed. It was then hypothesized that one of the amines in the
reaction was acting as a base and that adding a catalytic amount of base to the reaction
could be killing the chemistry, because the solution would become too basic. This
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method was tried with the isocyanate group on the dibrominated aniline, but showed no
evidence of a urea functional group either.
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Figure 3-4: Synthesis of the urea analogue (27) scheme 2

3.2: Reverse Carbamate
The next analogue attempted was the reverse carbamate (5) (Figure 3-6), which
used the method where the isocyanate was on dibrominated amino coumaranone, since
the linear chain had a terminal alcohol (25) and therefore could not form an isocyanate
group. Using the same method as the urea analogue, an isocyanate group was formed on
the dibrominated amino coumaranone (28), which was then reacted with the hydroxy
linear chain (Figure 3-5).19,30,31 An 1H NMR spectrum did not contain an N-H peak,
suggesting that the carbamate had not formed. This reaction was then repeated multiple
times, with no evidence of the carbamate forming. A new method was then devised that
used a chloroformate functional group instead of an isocyanate. Using a chloroformate
allowed the highly reactive functional group to be on placed on the primary hydroxy
group of the linear chain, as in the clavatadine A synthesis. It was hypothesized that
having an isocyanate on the dibrominated amino coumaranone (27) made the isocyanate
20

less likely to react due to steric hindrance of the bromines or possible electrical

Figure 3-5: Synthesis of the reverse carbamate (29) scheme 1

interference from the coumaranone. This method was then tested by reacting the linear
chain with a terminal hydroxy group with triphosgene to form a chloroformate (30)

Figure 3-6: Synthesis of chloroformate (30)

(Figure 3-6).32,33 1H NMR and FTIR spectroscopy confirmed that the chloroformate (30)
had been formed; therefore it was quickly dissolved in dichloromethane and had a
catalytic amount of base added to it before dibrominated amino coumaranone (14) was
added dropwise (Figure 3-7).34 This reaction also produced no evidence of the carbamate
forming.
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3.3: Testing the Chemistry
Since none of these reactions formed the desired product, a series of test reactions
was designed and performed to determine if there was something wrong with the

Figure 3-7: Synthesis of reverse carbamate (29) scheme 2

chemistry of the reactions, or if other errors occurred. The first series of reactions used
two compounds that were already in the lab that could form a carbamate and that were
similar to the subunits of the analogues, specifically benzyl chloroformate (32) and ptoluidine (31). First, p-toluidine was dissolved in tetrahydrofuran and a catalytic amount

Figure 3-8: Test reaction to form carbamate

of imidazole was added to the solution. Then, the benzyl chloroformate was added
dropwise, and this reaction was left to stir over night (Figure 3-8).35 This reaction did
show evidence of a carbamate forming, with an N-H peak at 6.72 ppm, that matched
22

reported spectra of the compound.35 The next test reaction involved reacting the
dibrominated amino coumaranone (14) with benzyl chloroformate (32) using identical
conditions to see if there was something wrong with the chemistry, since user error had
been ruled out when the test reaction formed a carbamate. Following the same method as
the first test reaction the second test reaction was performed, with no evidence of a
carbamate being formed. This reaction was then performed multiple times using a
variation of stronger and weaker bases, with still no evidence of a carbamate being
formed. The next test reaction involved reacting the amino coumaranone (13) with benzyl
chloroformate (32) to see if the bromines were sterically hindering the reaction to
combine the two subunits. Using the same conditions as the first test reaction benzyl
chloroformate (32) and amino coumaranone (13) were reacted together. The 1H NMR
spectrum of the crude product of the reaction showed promise, with some evidence of
carbamate N-H peaks from a formed carbamate. Another test reaction on a larger scale
will have to be conducted before the actual chloroformate subunit is used on amino
coumaranone.
After running several different test reactions it was hypothesized that the
bromines on the ring of the dibrominated coumaranone coupled with the amine was
causing some form of 1,3-allylic strain that hindered the carbamate forming reactions.
Usually allylic strain is seen when substituents the size of methyl groups get to close to
each other, in this case it is most likely due to the hydrogens of the amine and the
bromines being too close to each other. To avoid strain as much as a possible the
molecule likely has the lone pair of the amine in the plane of the ring directed at one of
23

the bromines, while the hydrogens are on opposite sides of the ring flanking the other
bromine. This conformation leaves the lone pair of the amine hindered and unable to
attack the carbonyl carbon of an isocyanate or chloroformate functional group. This
hypothesis is supported by the fact that the alcohol on the dibrominated homogentisic
acid lactone readily reacts with an isocyanate. This is because dibrominated homogentisic
acid lactone in any conformation will always have a lone pair that is unhindered and
accessible.
3.4: Five Carbon Clavatadine A
The last analogue that was attempted was the five carbon linear chain clavatadine
A (35), this molecule is exactly the same as clavatadine A except it has one extra carbon
on its linear, guanidine containing subunit. This analogue is a desired target because the
one extra carbon on the linear chain could move the carbonyl carbon of the carbamate far
enough away from serine 195 of factor XIa to keep it from binding covalently. To make
this analogue the same synthesis route to make clavatadine A was used, except that 1,5Br
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Figure 3-9: Synthesis of five carbon clavatadine A precursor (34)

diaminobutane was used to make the linear subunit (21).19 As in the synthesis of
clavatadine A the reaction between the isocyanate and the lactone (Figure 3-9) was
24

almost immediate, and a strong spot not correlating to starting material appeared by TLC
after fifteen minutes. The crude 1H NMR spectrum showed an extra peak at 7.24 ppm,
which was originally thought to be the N-H peak, but after purifying the material by
column chromatography the real N-H peak appeared at 5.33 ppm as a broad triplet. The
precursor to the extra carbon clavatadine A (34) had been made successfully, and then
just need to bwreacted with HCl to open up the lactone and deprotect the guanidine to
give the first completed analogue.
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Figure 3-10: Convert five carbon clavatadine A precursor to completed analogue
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APPENDIXES
Appendix A
Experimental/Suppleamental data

All solvents and reactants that were used were purchased from Sigma-Aldrich
Chemical Supply Company, VWR Chemical Supply Company, or the ACROS Chemical
Supply company. Nitrogen gas used to produce an inert atmosphere, and hydrogen gas to
produce a hydrogen atmosphere were provided by the Central Washington University
Chemistry department and was purchased from OXARC. All flash column
chromatography used EMD silica gel 60, 230-400 mesh.

Di-Boc guanidine1 (21): To a solution of 1,5-pentanediamine (20) (0.385 mL, 3.269
mmol, 3.0 equiv) in 5 mL of CH2Cl2 was added Et3N (0.151 mL, 1.09 mmol, 1.0 equiv).
Then, a solution of N,Nʹ-di-Boc-N-triflylguanidine (17) (Goodman’s reagent) (426.7 mg,
1.09 mmol, 1.0 equiv) in 5 mL of CH2Cl2 was added dropwise by addition funnel over 1 h
(the reaction mixture grew cloudy), and the reaction mixture was stirred at ambient
temperature for 12 h. Goodman’s reagent was prepared following the procedure published
by Goodman et al.2 After 12 h, the reaction mixture was gravity filtered to remove
suspended solids, and then was washed with saturated aqueous NaHCO3 (2 × 3 mL), H2O
(2 × 3 mL), and brine (1 × 3 mL), dried over anhydrous Na2SO4, filtered, and concentrated
in vacuo. Purification by flash column chromatography on silica gel (5:3:2
EtOAc/MeOH/Et3N) afforded the product as a white powder (333.4 mg, 89%): Rf = 0.36,
27

5:3:2 EtOAc/MeOH/Et3N; 1H NMR (CDCl3, 400 MHz) δ 11.50 (br s, 1H), 8.31 (br s, 1H),
3.42 (dt, J = 7.2, 5.2, 2H), 2.70 (dt, J = 7.2, 6.8, 2H), 1.59 (quint, J = 7.2, 2H) 1.52–1.47
(m, 2H), 1.51 (s, 9H), 1.50 (s, 9H), 1.42–1.36 (m, 2H);

13

C NMR (CDCl3, 100 MHz) δ

163.7, 156.1, 153.4, 83.0, 79.2, 42.0, 40.8, 33.4, 28.9, 28.3, 28.1, 24.2;

Di-Boc guanidine1 (19): To a solution of 1,4-butanediamine (18) (3.10 mL, 26.4 mmol,
3.0 equiv) in 365 mL of CH2Cl2 was added Et3N (1.22 mL, 8.78 mmol, 1.0 equiv). Then,
a solution of N,N’-di-Boc-N”-triflylguanidine2 (3.436 g, 8.78 mmol, 1.0 equiv) in 15 mL
of CH2Cl2 was added dropwise by addition funnel over 1 h (the reaction mixture grew
cloudy), and the reaction mixture was stirred at ambient temperature for 12 h. After 12 h,
the reaction mixture was gravity filtered to remove suspended solids, and then was washed
with saturated aqueous NaHCO3 (2 × 50 mL), H2O (2 × 50 mL), and brine (1 ×50 mL),
dried over anhydrous Na2SO4, filtered, and concentrated in vacuo. Purification by flash
column chromatography on silica gel (5:3:2 EtOAc/MeOH/Et3N) afforded the product as
a pale yellow oil (2.663 g, 98%): Rf = 0.39, 5:3:2 EtOAc/MeOH/Et3N; 1H NMR (CDCl3,
400 MHz) δ 11.50 (br s,1H), 8.35 (br s, 1H), 3.43 (td, J = 7.2, 4.8, 2H) 2.74 (t, J = 7.0, 2H),
1.63 (m, 2H), 1.53 (m, 2H), 1.51 (s, 9H), 1.49 (s, 9H);
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C NMR (CDCl3, 100 MHz) δ

163.6, 156.2, 153.3, 83.1, 79.3, 41.8, 40.7, 30.8, 28.3, 28.1, 26.4

Linear chain isocyanate1,3 (26): To a 25 mL round-bottom flask was added 20 mg of
amine (19) (20 mg, 0.0581 mmol, and 1 equiv), 1 mL of CH2Cl2,. This solution was then
cooled to 0 ºC using an ice-water bath, and then the solution was then charged with 6.8 mg
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of triphosgene (6.8 mg, 0.0232 mmol, and 0.4 equiv). To this solution was added 1 mL of
saturated NaHCO3, and the mixture was left to stir for 30 min at 0 ºC. The solution was
then diluted with 3 mL of CH2Cl2 and 3 mL H2O. The organic layer was removed and the
aqueous layer was extracted with 2 × 3 ml CH2Cl2. The combined organic layers were
washed with 10 mL of H2O and 10 mL of brine, and over anhydrous Na2SO4, filtered and
concentrated in vacuo to give 22.5 mg (107%) of white powder:

Nitro-Coumaranone4 (12): To a 25 mL round-bottomed flask was added concentrated
nitric acid(0.697 mL, 15.5 mmol, 4.16 equiv) and concentrated sulfuric acid (0.663 mL,
12.45 mmol, 3.34 equiv). This solution was then cooled to 5 °C using an ice-water bath.
Then, a solution of 2-coumaranone (11) (0.500 g, 3.727 mmol, 1.0 equiv) in 0.860 mL of
acetic acid was added dropwise to the cooled acid solution. Yellow crystals appeared
immediately. This solution was the left to stir for 20 minutes at 5 °C. After stirring, ice and
water were added to the mixture. The resulting yellow powder were then filtered and
washed with methyl tert-butyl ether, and left to dry. The dry yellow powder weighed
0.4085g (61% yield): 1H NMR (DMSO-d6, 400 MHz) δ 8.27 (dd, J = 11.8, 2H), 7.43 (d,
1H), 4.04 (s, 2H); 13C NMR (CDCl3, 100 MHz) δ 173.42, 158.76, 143.59, 126.42, 125.02,
120.53, 110.76, 32.76

Amino Coumaranone (13): To a flame-dried 25 mL round-bottom flask under an N2
atmosphere was added 50 mg of nitro-coumaranone (12) (50 mg, 0.277 mmol, and 1.0
equiv) and 8 mL of EtOAc. This solution was then charged with a spatula-tip full of 10%
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palladium on carbon catalyst. The flask was then flushed with H2 gas, and left with a
balloon of H2 gas while the solution stirred for 2 h or until starting material disappeared
from TLC. The palladium was then filtered off and the resulting solution was concentrated
in vacuo. The dry white powder weighed 40.8 mg (98% yield): 1H NMR (DMSO, 400
J = 8.4,1H), 6.55 ( s, 1H), 6.46 (dd, J =6.2, 2H), 4.93 (br s, 2H), 3.78 (s,
2H);

C NMR (DMSO-d6, 100 MHz) δ 175.0, 145.34, 144.94, 124.43, 112.63, 110.17,
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110.07, 33.06

Dibromoaniline5 (14): To a flame dried 25 mL round-bottomed flask under an N2
atmosphere was added 50 mg of amino coumaranone (13) (50 mg, 0.333 mmol, and 1.0
equiv) and 8 mL of ethyl acetate. This solution was then cooled to -78 ºC. The flask was
then charged with Br2 (0.0513 mL, 0.990 mmol, 3.0 equiv). This solution was then allowed
to stir for 6 hours and the disappearance of starting material: 1H NMR (DMSO-d6, 400
MHz) δ 7.41 (s, 1H), 5.16 (br s, 2H), 3.82 (s, 2H); 13C NMR (CDCl3, 100 MHz) δ 172.07,
145.81, 138.94, 124.81, 114.0, 107.38, 104.91, 35.20

Aniline isocyanate6,7(27): To a 25 mL round-bottomed flask was added 100 mg of
dibrominated aniline (14) (100 mg, 0.3258 mmol, 1 equiv), 4 mL of CH2Cl2, and 4.5 µL
of triethylamine. This solution was then cooled to 0 ºC using an ice-water bath, the solution
was then charged with 96.7 mg of triphosgene (96.7 mg, 0.3258 mmol, 1 equiv). This
solution was left to stir for 30 min at 0 ºC, then 1 h at room temperature. The solution was
then heated at reflux for 5 h. Then the solution was allowed to cool to room temperature,
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and then diluted with 3 mL ethyl acetate and 3 mL H2O. The organic layer was removed
and the aqueous layer was extracted with 2 × 3 ml CH2Cl2. The combined organic layers
were washed with 10 mL H2O and 10 mL brine, and dried over anhydrous Na2SO4 filtered
and concentrated in vacuo to give 86.8 mg (79%) of orange powder:

N,Nʹ-Bis(tert-butoxycarbonyl)-S-methyl-isothiourea8,9 (23): To a clean 25 mL roundbottomed flask was added 2-methyl-2-thiopseudourea (100 mg, 0.719 mmol, 1.0 equiv)
and was then dissolved in 1.5 mL of CH2Cl2. To this solution was added 627 mg di-tertbutyl dicarbonate (627 mg, 2.876 mmol, and 4.0 equiv) and 1.44 mL of NaHCO3. This
solution was then left to stir for 18 hours. The layers were separated, and the aqueous phase
extracted with CH2Cl2. The resulting organic solution was dried over anhydrous Na2SO4,
filtered and concentrated in vacuo. The product was then purified using column
chromatography (1:3 EtOAc/Et2O). The resulting white powder weighed 95.1 mg (82%
yield): 1H NMR (CDCl3, 400 MHz) δ 11.61 (br s, 1H), 2.40 (br s, 1H), 1.52 (s, 9H), 1.51
(s, 9H),

N,Nʹ-Bis(tert-butoxycarbonyl)-Nʺ-(4-hydroxypentyl)guanidine (25)8,9: To a clean 25
mL round-bottomed flask was added N,Nʹ-bis(tert-butoxycarbonyl)-S-methyl-isothiourea
(95.1 mg, 0.327 mmol, 1.0 equiv) and 67 mg of 5-amino-1-butanol (67 mg, 0.654 mmol,
2.0 equiv) in 3 mL of THF. This solution was then heated at 50 °C for 2 h, and allowed to
cool to room temperature. The solution was then diluted with 3 mL of CH 2Cl2 and 3 mL
of H2O. The organic layer was removed and the aqueous layer was extracted with 2 × 3 ml
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of CH2Cl2. The combined organic layers were washed with 10 mL of H2O and 10 mL of
brine, and dried over Na2SO4, filtered, and concentrated in vacuo to give 92.7 mg (94%)
of white solid: 1H NMR (CDCl3, 400 MHz) δ 11.50 (br s, 1H), 8.32 (br s, 1H), 3.66 (t, J =
6.4, 2H), 3.42 (dd, J = 5.6, 6.8, 2H), 1.59 (quint, J = 7.2, 2H) 1.52–1.47 (m, 2H), 1.51 (s,
9H), 1.50 (s, 9H), 1.42–1.36 (m, 2H);

C NMR (CDCl3, 100 MHz) δ 163.60, 156.17,
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153.34,83.08, 79.29, 62.60, 40.78, 32.29, 28.86, 28.31, 28.09, 23.05

Chloroformate10,11 (30): To a clean, dry 25 mL round-bottomed flask was added N,Nʹbis(tert-butoxycarbonyl)-Nʺ-(4-hydroxypentyl)guanidine (30 mg, 0.0868 mmol, 1.0 equiv)
and 2 mL of CH2Cl2. To this solution was added 6.87 mg of pyridine (7 µL, 0.0868 mmol,
1.0 equiv), and it was cooled to 0 °C using an ice-water bath. Once cooled, triphosgene
(7.731 mg, 0.026 mmol, 0.3 equiv) was added to the solution, and it was then left to stir
for 4 hours. The solution was then diluted with 3 mL of CH2Cl2 and 3 mL of H2O. The
organic layer was removed and the aqueous layer was extracted with 2 × 3 ml CH2Cl2. The
combined organic layers were washed with 10 mL of H2O and 10 mL of brine, and dried
over Na2SO4, filtered, and concentrated to give 24.5 mg (70%) of a transparent syrup. 1H
NMR (CDCl3, 400 MHz) δ 11.50 (br s, 1H), 8.36 (br s, 1H), 4.33 (t, J = 6.4, 2H) 3.44 (dd,
J = 5.6, 6.8, 2H) 1.77 (quint, J = 7.2, 2H) 1.62 (quint, J = 7.6 2H), 1.50 (s, 18H)

5 Carbon Clavatadine A precursor1 (33): To a clean dry 25 mL round-bottomed flask
was added 30 mg dibrominated homogentisic acid lactone (2) (41.6 mg, 0.1351 mmol, 1.0
equiv), 1 mL of CH2Cl2, and Hünig’s base (4.61 µL, 0.02702 mmol, 0.2 equiv). To this
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solution was added linear chain isocyanate (35) (50 mg, 0.1351 mmol, 1.0 equiv), and was
then left to stir for 1 h. The solution was then diluted with 3 mL of CH2Cl2 and 3 mL of
H2O. The organic layer was removed and the aqueous layer was extracted with 2 × 3 ml of
CH2Cl2. The combined organic layers were washed with 10 mL of H2O and 10 mL of brine,
and dried over Na2SO4, filtered, and concentrated to give 35.4 mg (70%) of a wet purple
powder. Purification by flash column chromatography on silica gel afforded the product as
a purple powder: 1H NMR (CDCl3, 400 MHz) δ 11.50( br s, 1H), 8.325 (br s, 1H), 7.322
(s, 1H), 5.328 (t, J = 5.76, 1H), 3.69 (s, 2H), 3.48 (dd, J = 6.8, 7.2, 2H), 3.44 (m, 2H), 3.32
(dd, J = 6.4, 6.8 ,2H) 1.62 (m, 4H), 1.50 (s, 18H); 13C NMR (CDCl3, 100 MHz) δ 171.35,
163.59, 156.20, 153.36, 152.14, 151.68, 142.61, 125.22, 118.24, 115.01, 114.35, 83.16,
79.34, 41.25, 40.53, 34.72, 29.26, 28.60, 23.69

N,Nʹ-Bis(tert-butoxycarbonyl)-Nʺ-(4-hydroxypentyl)guanidine1 (25): To a solution of
5-amino-1-butanol (0.337 g, 3.269 mmol, 3.0 equiv) in 5 mL of CH2Cl2 was added Et3N
(0.151 mL, 1.09 mmol, 1.0 equiv). Then, a solution of N,Nʹ-di-Boc-N-triflylguanidine (17)
(Goodman’s reagent) (426.7 mg, 1.09 mmol, 1.0 equiv) in 5 mL of CH2Cl2 was added
dropwise by addition funnel over 1 h (the reaction mixture grew cloudy), and the reaction
mixture was stirred at ambient temperature for 12 h. Goodman’s reagent was prepared
following the procedure published by Goodman et al.2 After 12 h, the reaction mixture was
gravity filtered to remove suspended solids, and then was washed with saturated aqueous
NaHCO3 (2 × 3 mL), H2O (2 × 3 mL), and brine (1 × 3 mL), dried over anhydrous Na2SO4,
filtered, and concentrated in vacuo, this afforded the product as a white powder (369.3 mg,
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98%):1H NMR (CDCl3, 400 MHz) δ 11.50 (br s, 1H), 8.32 (br s, 1H), 3.66 (t, J = 6.4, 2H),
3.42 (dd, J = 5.6, 6.8, 2H), 1.59 (quint, J = 7.2, 2H) 1.52–1.47 (m, 2H), 1.51 (s, 9H), 1.50
(s, 9H), 1.42–1.36 (m, 2H); 13C NMR (CDCl3, 100 MHz) δ 163.60, 156.17, 153.34,83.08,
79.29, 62.60, 40.78, 32.29, 28.86, 28.31, 28.09, 23.05
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Appendix B
Spectroscopic Data
All NMR spectroscopic data was collected using a Bruker Avance 400
spectrometer at 400 MHz for 1H NMR and at 100MHz for 13C NMR. All infrared
spectroscopy spectral data was collected using a Bruker Alpha, with a universal sample
module with polished sodium chloride plates, or by using the platinum ATR module.
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Figure A2-1: 1H NMR spectrum of nitro coumaranone (12)
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Figure A2-2: 13C NMR spectrum of nitro coumaranone (12)
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Figure A2-3: 1H NMR spectrum of amino coumaranone (13)
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Figure A2-4: 13C NMR spectrum of amino coumaranone (13)
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Figure A2-5: 1H NMR spectrum of dibrominated amino coumaranone (14)
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Figure A2-6: 13C NMR spectrum of dibrominated amino coumaranone (14)
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Figure A2-7: Infrared spectrum of dibrominated coumaranone isocyanate (27)
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Figure A2-8: 1H NMR spectrum of four carbon linear guanidine containing chain (19)
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Figure A2-9: 13C NMR spectrum of four carbon linear guanidine containing chain (19)
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Figure A2-10: Infrared spectrum of four carbon linear guanidine containing chain isocyanate (26)
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Figure A2-11: 1H NMR spectrum of five carbon linear guanidine containing chain (21)
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Figure A2-12: 13C NMR spectrum of four carbon linear guanidine containing chain (21)
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Figure A2-13: 1H NMR spectrum of N,Nʹ-bis(tert-butoxycarbonyl)-S-methyl-isothiourea (23)
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Figure A2-14: 1H NMR spectrum of alcohol linear guanidine containing chain (25)
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Figure A2-15: 13C NMR spectrum of alcohol linear guanidine containing chain (25)
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Figure A2-16: Infrared spectrum of alcohol linear guanidine containing chain (25)
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Figure A2-17: 1H NMR spectrum of chloroformate linear guanidine containing chain (30)
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Figure A2-18: Infrared spectrum of chloroformate linear guanidine containing chain (30)
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Figure A2-19: 1H NMR spectrum of five carbon clavatadine A precursor (33)

55
Figure A2-20: 13C NMR spectrum of five carbon clavatadine A precursor (33)

